REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection

Abstract

Abstract Patients with lymphoproliferative diseases are at high risk for SARS‐CoV‐2‐related complications and mortality. The role of casirivimab and imdevimab (REGEN‐COV), a neutralizing antibody cocktail, to treat immunocompromised hemato‐oncological patients with SARS‐CoV‐2 disease 2019 (Covid‐19) remains unknown. Here, we present our clinical experience on the outcome of 15 hematological patients treated with REGEN‐COV for SARS‐CoV‐2 infection. Most patients failed to respond or achieved low antibody titer after 2–3 doses of BNT162b2 mRNA vaccine. All patients experienced clinical improvement with no mortality within a median follow‐up of 70 days. In conclusion, early administration of REGEN‐COV to high‐risk hematological patients may prevent clinical deterioration and mortality from SARS‐CoV‐2 infection. The effectiveness of neutralizing antibodies may vary depending on the virus variants and in particular with the omicron variant (B.1.1.529).

Keywords

• Covid‐19
• lymphoproliferative malignancies
• REGEN‐COV
• SARS‐Cov‐2